By Kate Hammeke, VP of Market Research, Industry Standard Research (ISR)
Over the past year, COVID-19 has impacted just about every aspect of our personal and professional lives. The pharmaceutical industry rose to myriad challenges brought on by the global pandemic. One of the high points has been the development, testing, and approval of multiple coronavirus vaccines in record time. The immediate and unpredicted need for billions of doses of a vaccine sent tidal waves through the biopharma industry, derailed strategic plans set in place years ago, and forced pharmaceutical companies to shift resources.